“…Insertion failure (median 5.8%, range 0–22%), epistaxis (median 2.7%, range 0–33%), and nasal pain (median 35%, range 0–58.3%) associated with UT‐EGD have been reported in the literature, but their ranges are too wide, so is the median visual analogue scale (VAS, 0–5) for nasal pain (1.4 ± 0.4, range 0.8–1.9) . In contrast, the average nasal pain (2.5 ± 0.8, range 1.2–3.7), insertion failure (3.1%, range 0–10.9%), and epistaxis (4.7%, range 0–8.9%) are more convergent and thus reliable to reflect the real‐world data from my study seriers . In brief, the approximately average side effect triad nasal pain (~VAS 2), insertion failure (~3%), and epistaxis (~4%) are tempting for inexperienced endoscopists and patients to accept UT‐EGD.…”